US health agency launches SPECTRA autism research program using biological and real-world data

The Advanced Research Projects Agency for Health has launched SPECTRA, a research program combining biological, clinical, behavioral and real-world data with computational methods to investigate variation in autism and inform its assessment and care.

The Baseline

• The Advanced Research Projects Agency for Health has launched SPECTRA to investigate variation in autism and individual trajectories over time.
• The program will combine biological, clinical, behavioral and real-world data with computational methods.
• Research will focus on autism assessment, modeling, individualized interventions and technologies supporting communication and quality of life.

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the US Department of Health and Human Services (HHS), has announced a new research effort focused on understanding differences in how autism presents and develops across individuals. The program will also explore technologies that could support assessment and intervention across the lifespan.

The Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency (SPECTRA) program will examine developmental, health, communication and functional trajectories among people with autism spectrum disorder (ASD), including how genetic, environmental and biological factors may contribute to differences between individuals. SPECTRA follows the launch of the National Institutes of Health’s $50 million Autism Data Science Initiative, which is supporting 13 projects using large-scale data to investigate factors contributing to autism and associated outcomes.

Around 1 in 31 children aged 8 years across 16 US communities was identified with ASD in 2022. Needs and abilities vary considerably among autistic people, and autism can occur alongside conditions including sleep and gastrointestinal disorders and intellectual disability. Understanding these differences, and how individual trajectories change over time, is a central focus of SPECTRA.

Autism diagnosis currently relies primarily on behavioral observation by trained professionals, which can be time intensive and costly, while access to specialists is limited in some areas. Assessments also typically take place after developmental differences have emerged. Evidence suggests that earlier identification and access to appropriate care during key developmental periods may provide benefits for some autistic children.

Russell Shilling, SPECTRA Program Manager, said variation among autistic people informed the program’s approach:

“Over the past decade, we have become much better at recognizing autism and the substantial differences among people across the spectrum. Yet our approaches to assessment and care have not kept pace, and they overlook the behavioral and biological complexity of each person. SPECTRA is designed around that complexity.”

He added that the program will combine “advanced health technologies, next-generation computational tools, and the lived experience of the autism community”. Working with stakeholders and advocacy groups, SPECTRA will integrate clinical, behavioral and real-world measures with biological data, including genetic factors, environmental exposures, epigenetic features, microbiome biology and other omics data. Researchers will use these data to develop nonlinear computational models of ASD subtypes and examine how different factors may interact to shape individual trajectories.

Research will span four areas:

1. Analysis will examine genetic, environmental, family, metabolic, immune and developmental factors associated with different trajectories.
2. Modeling will focus on federated, privacy-preserving AI platforms designed to map these trajectories and identify potentially modifiable outcome drivers and actionable targets.
3. Precision Intervention will investigate individualized selection and testing of interventions across the lifespan.
4. Enabling Technologies will focus on tools for communication, quality of life and embedded assessment, including approaches that measure real-world function through ordinary use.

The program is intended to support an end-to-end system for identifying ASD risk factors, matching individuals with appropriate interventions and facilitating clinical research into adaptive therapies. HHS Secretary Robert F. Kennedy, Jr. said of SPECTRA:

 “Autism is not one-size-fits-all, and our science and care cannot be either. Millions of American families are impacted by autism, and they need better answers about why it presents so differently from one person to another and which approaches can best meet each person's needs.”